OncoFirm’s products, services, and content are intended for licensed medical distributors, healthcare professionals, and institutional buyers only. We do not sell or promote our rapid diagnostic tests directly to consumers or patients.
OncoFirm Diagnostics Corp. (a registered Delaware Corporation) for the development of Early Cancer Rapid Tests, we are in a premarket investment phase. Our mission will be in revolutionizing early rapid cancer diagnostics through cutting-edge Fluorescent Lateral Flow Tests (FLFTs) and traditional lateral flow assay (LFA) technology. Our proprietary rapid diagnostic solutions utilize various antigens, with highly specific biomarkers linked to cancer progression, to provide accurate, fast, and accessible screening tools. Available to hospitals, clinics, and diagnostic labs, cancer screening and progression programs, research in oncology and infectious diseases… Investor Disclaimer (1)